Profund Advisors
CRVS icon

Profund Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Profund Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$321K Sell
27,895
-13,149
-32% -$183K 0.01% 722
2026
Q2 		$613K Sell
41,044
-9,191
-18% -$128K 0.02% 489
2026
Q1 		$735K Buy
50,235
+13,172
+36% +$210K 0.03% 433
2025
Q4 		$285K Buy
+37,063
New +$292K 0.01% 911

Other funds holding CRVS

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $444M AUM 151.5% 1-Year Est. Return

Profund Advisors's CRVS Position: Q3 2026 in Review

Profund Advisors reduced its Corvus Pharmaceuticals (CRVS) stake by 32% in Q3 2026, selling an estimated $183K and leaving 27,895 shares worth $321K. The position accounts for 0.01% of the portfolio, ranked #722.

Profund Advisors first reported a position in CRVS in Q4 2025 and has held it in 4 quarters since. The position peaked at $735K in Q1 2026. 123 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Profund Advisors held 27,895 shares of Corvus Pharmaceuticals worth $321K as of Q3 2026.
  • Profund Advisors sold 13,149 Corvus Pharmaceuticals shares in Q3 2026, an estimated $183K.
  • Corvus Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #722 holding.
  • Profund Advisors first reported a position in Corvus Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Profund Advisors's Corvus Pharmaceuticals position peaked at $735K in Q1 2026.
  • 123 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.